Publications

BibTex format

@article{Mateos:2021:10.1186/s13045-021-01071-9,
author = {Mateos, MV and Gavriatopoulou, M and Facon, T and Auner, HW and Leleu, X and Hajek, R and Dimopoulos, MA and Delimpasi, S and Simonova, M and Spicka, I and Pour, L and Kriachok, I and Pylypenko, H and Doronin, V and Usenko, G and Benjamin, R and Dolai, TK and Sinha, DK and Venner, CP and Garg, M and Stevens, DA and Quach, H and Jagannath, S and Moreau, P and Levy, M and Badros, AZ and Anderson, LD and Bahlis, NJ and Cavo, M and Chai, Y and Jeha, J and Arazy, M and Shah, J and Shacham, S and Kauffman, MG and Richardson, PG and Grosicki, S},
doi = {10.1186/s13045-021-01071-9},
journal = {Journal of Hematology and Oncology},
title = {Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma},
url = {http://dx.doi.org/10.1186/s13045-021-01071-9},
volume = {14},
year = {2021}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Elderly and frail patients with multiple myeloma (MM) are more vulnerable to the toxicity of combination therapies, often resulting in treatment modifications and suboptimal outcomes. The phase 3 BOSTON study showed that once-weekly selinexor and bortezomib with low-dose dexamethasone (XVd) improved PFS and ORR compared with standard twice-weekly bortezomib and moderate-dose dexamethasone (Vd) in patients with previously treated MM. This is a retrospective subgroup analysis of the multicenter, prospective, randomized BOSTON trial. Post hoc analyses were performed to compare XVd versus Vd safety and efficacy according to age and frailty status (<65 and ≥65 years, nonfrail and frail). Patients ≥65 years with XVd had higher ORR (OR 1.77, p = .024), ≥VGPR (OR, 1.68, p = .027), PFS (HR 0.55, p = .002), and improved OS (HR 0.63, p = .030), compared with Vd. In frail patients, XVd was associated with a trend towards better PFS (HR 0.69, p = .08) and OS (HR 0.62, p = .062). Significant improvements were also observed in patients <65 (ORR and TTNT) and nonfrail patients (PFS, ORR, ≥VGPR, and TTNT). Patients treated with XVd had a lower incidence of grade ≥ 2 peripheral neuropathy in ≥65 year-old (22% vs. 37%; p = .0060) and frail patients (15% vs. 44%; p = .0002). Grade ≥3 TEAEs were not observed more often in older compared to younger patients, nor in frail compared to nonfrail patients. XVd is safe and effective in patients <65 and ≥65 and in nonfrail and frail patients with previously treated MM.
AU  - Mateos,MV
AU  - Gavriatopoulou,M
AU  - Facon,T
AU  - Auner,HW
AU  - Leleu,X
AU  - Hajek,R
AU  - Dimopoulos,MA
AU  - Delimpasi,S
AU  - Simonova,M
AU  - Spicka,I
AU  - Pour,L
AU  - Kriachok,I
AU  - Pylypenko,H
AU  - Doronin,V
AU  - Usenko,G
AU  - Benjamin,R
AU  - Dolai,TK
AU  - Sinha,DK
AU  - Venner,CP
AU  - Garg,M
AU  - Stevens,DA
AU  - Quach,H
AU  - Jagannath,S
AU  - Moreau,P
AU  - Levy,M
AU  - Badros,AZ
AU  - Anderson,LD
AU  - Bahlis,NJ
AU  - Cavo,M
AU  - Chai,Y
AU  - Jeha,J
AU  - Arazy,M
AU  - Shah,J
AU  - Shacham,S
AU  - Kauffman,MG
AU  - Richardson,PG
AU  - Grosicki,S
DO  - 10.1186/s13045-021-01071-9
PY  - 2021///
SN  - 1756-8722
TI  - Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
T2  - Journal of Hematology and Oncology
UR  - http://dx.doi.org/10.1186/s13045-021-01071-9
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000640253700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/89189
VL  - 14
ER  -

Download

ProfessorHolgerAuner

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)